Oncology Pharma Inc. (ONPH)
| Market Cap | 2.32M +11,899.8% |
| Revenue (ttm) | 10.21K -98.4% |
| Net Income | 186.04K |
| EPS | n/a |
| Shares Out | 38.66M |
| PE Ratio | 12.47 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,217 |
| Open | 0.0300 |
| Previous Close | 0.0443 |
| Day's Range | 0.0300 - 0.0618 |
| 52-Week Range | 0.0001 - 0.3640 |
| Beta | -6.67 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Oncology Pharma
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California. [Read more]
Financial Performance
In fiscal year 2013, Oncology Pharma's revenue was $10,214, a decrease of -92.42% compared to the previous year's $134,700. Earnings were $186,035, an increase of 216.79%.
Financial StatementsNews
Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery.
Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the fi...
Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to be reviewing the financing for taking the steps on moving fo...
Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development
SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased that the initial feasibility stage is complete and results have ...
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development
SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to execute its next phase with Connect2Trials, Inc. Originally, t...
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
SAN FRANCISCO, CA / ACCESSWIRE / April 13, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma ("The Company") is pleased to announce that it has completed the initial feasibility phase of its...
Oncology Pharma Reports on Progress with Ribera Solutions
SAN FRANCISCO, CA / ACCESSWIRE / March 2, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce progress with its investment with Ribera Solutions'...
Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") looks toward releasing further results of the studies under the Co-Dev...
Oncology Pharma Expands on Feasibility Studies and Data
SAN FRANCISCO, CA / ACCESSWIRE / February 17, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") wants to expand on a previously announced press release that included ...
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC PINK:RGBPP): announced that they intend to...
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
SAN FRANCISCO, CA / ACCESSWIRE / February 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce that the co-development agreement and ongoing wo...
Oncology Pharma's New Year Update
SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") update on its progress to kick off the new year. The Company has advanc...
Oncology Pharma Meeting Towards Future Developments
SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. ("The Company") conducted a meeting with the Board of Directors, executives, and Scienti...
Oncology Pharma Year End Review and Outlook
SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") and its Chief Executive are pleased to give a year end update and provi...
Oncology Pharma Research and Vision
SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is a pioneering oncology company dedicated to providing the financing ...
Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Oncology Pharma, Inc. (the "Company") is pleased to provide some insight into the progress of its co-development project with NanoSmart Pharmaceutic...
Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
SAN FRANCISCO, CA / ACCESSWIRE / October 27, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previous communications, Oncology Pharma, Inc. (the "Company") is making progress towards pursuing ...
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. (the "Company") has retained the services...
Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
SAN FRANCISCO, CA / ACCESSWIRE / October 12, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") would like to update investors on its progress. The Company is in the fin...
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
SAN FRANCISCO, CA / ACCESSWIRE / September 13, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH). In keeping with management's commitment to continue implementation of Oncology Pharma's ("the Company") cap...
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH) defines its objective and strategy for recently signed Co-Development deal. The primary goal of the Co-Developm...
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceut...
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward. Fr...
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
SAN FRANCISCO, CA / ACCESSWIRE / June 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is developing a program to establish the use of its license utilizing NR2F6 ...
Shares of This Biotech Stock Could Jump 437%
Published by: Tim Kraimer Oncology Pharma, Inc. (Symbol: ONPH) is a San Francisco-based biotech company that has been making one blockbuster announcement after the next. These announcements have sent ...